Home Alzheimer’s Disease David Cohn, MD, on Clinician Awareness About the COVID-19 Vaccine in Patients...

David Cohn, MD, on Clinician Awareness About the COVID-19 Vaccine in Patients With Cancer

A cancer care expert from The Ohio State University Comprehensive Cancer Hospital talks about what patients and their providers need to know about the COVID-19 vaccine.

CancerNetwork® was joined by David Cohn, MD, director of the Gynecologic Cancer Research at The Ohio State University Comprehensive Cancer Hospital, to discuss what clinicians treating patients with cancer should know about in regard to the coronavirus disease 2019 (COVID-19) vaccine and the effects in their patients.

Multiple stakeholders in the cancer community as well as The Centers for Disease Control (CDC) and Prevention have indicated that patients on active cancer therapy are amongst those with a critical need for immunization against the COVID-19 virus. In January 2021, the National Comprehensive Cancer Network released guidance regarding vaccinations in patients with cancer.

“Patients who are on active…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments